229 related articles for article (PubMed ID: 12095833)
1. Loss of fragile histidine triad (FHIT) expression and microsatellite instability in periocular sebaceous gland carcinoma in patients with Muir-Torre syndrome.
Holbach LM; von Moller A; Decker C; Jünemann AG; Rummelt-Hofmann C; Ballhausen WG
Am J Ophthalmol; 2002 Jul; 134(1):147-8. PubMed ID: 12095833
[TBL] [Abstract][Full Text] [Related]
2. Different genetic pathways in the development of periocular sebaceous gland carcinomas in presumptive Muir-Torre syndrome patients.
Goldberg M; Rummelt C; Foja S; Holbach LM; Ballhausen WG
Hum Mutat; 2006 Feb; 27(2):155-62. PubMed ID: 16395674
[TBL] [Abstract][Full Text] [Related]
3. Microsatellite instability and immunostaining for MSH-2 and MLH-1 in cutaneous and internal tumors from patients with the Muir-Torre syndrome.
Machin P; Catasus L; Pons C; Muñoz J; Conde-Zurita JM; Balmaña J; Barnadas M; Martí RM; Prat J; Matias-Guiu X
J Cutan Pathol; 2002 Aug; 29(7):415-20. PubMed ID: 12139636
[TBL] [Abstract][Full Text] [Related]
4. DNA mismatch repair defects and microsatellite instability status in periocular sebaceous carcinoma.
Rajan Kd A; Burris C; Iliff N; Grant M; Eshleman JR; Eberhart CG
Am J Ophthalmol; 2014 Mar; 157(3):640-7.e1-2. PubMed ID: 24321472
[TBL] [Abstract][Full Text] [Related]
5. Hypermethylation of the CDKN2A gene promoter is a frequent epigenetic change in periocular sebaceous carcinoma and is associated with younger patient age.
Liau JY; Liao SL; Hsiao CH; Lin MC; Chang HC; Kuo KT
Hum Pathol; 2014 Mar; 45(3):533-9. PubMed ID: 24440092
[TBL] [Abstract][Full Text] [Related]
6. Deletions of BRCA1/2 and p53 R248W gain-of-function mutation suggest impaired homologous recombination repair in fragile histidine triad-negative sebaceous gland carcinomas.
Becker K; Goldberg M; Helmbold P; Holbach LM; Loeffler KU; Ballhausen WG
Br J Dermatol; 2008 Dec; 159(6):1282-9. PubMed ID: 18717684
[TBL] [Abstract][Full Text] [Related]
7. An association between sebaceous carcinoma and microsatellite instability in immunosuppressed organ transplant recipients.
Harwood CA; Swale VJ; Bataille VA; Quinn AG; Ghali L; Patel SV; Dove-Edwin I; Cerio R; McGregor JM
J Invest Dermatol; 2001 Feb; 116(2):246-53. PubMed ID: 11180000
[TBL] [Abstract][Full Text] [Related]
8. The significance of DNA mismatch repair genes in the diagnosis and management of periocular sebaceous cell carcinoma and Muir-Torre syndrome.
Gaskin BJ; Fernando BS; Sullivan CA; Whitehead K; Sullivan TJ
Br J Ophthalmol; 2011 Dec; 95(12):1686-90. PubMed ID: 21979897
[TBL] [Abstract][Full Text] [Related]
9. Frequency of microsatellite instability in unselected sebaceous gland neoplasias and hyperplasias.
Kruse R; Rütten A; Schweiger N; Jakob E; Mathiak M; Propping P; Mangold E; Bisceglia M; Ruzicka T
J Invest Dermatol; 2003 May; 120(5):858-64. PubMed ID: 12713593
[TBL] [Abstract][Full Text] [Related]
10. Widespread microsatellite instability in sebaceous tumours of patients with the Muir-Torre syndrome.
Peris K; Onorati MT; Keller G; Magrini F; Donati P; Muscardin L; Höfler H; Chimenti S
Br J Dermatol; 1997 Sep; 137(3):356-60. PubMed ID: 9349329
[TBL] [Abstract][Full Text] [Related]
11. Microsatellite instability and expression of hMLH-1 and hMSH-2 in sebaceous gland carcinomas as markers for Muir-Torre syndrome.
Entius MM; Keller JJ; Drillenburg P; Kuypers KC; Giardiello FM; Offerhaus GJ
Clin Cancer Res; 2000 May; 6(5):1784-9. PubMed ID: 10815898
[TBL] [Abstract][Full Text] [Related]
12. MSH-6: extending the reliability of immunohistochemistry as a screening tool in Muir-Torre syndrome.
Chhibber V; Dresser K; Mahalingam M
Mod Pathol; 2008 Feb; 21(2):159-64. PubMed ID: 18065960
[TBL] [Abstract][Full Text] [Related]
13. Loss of mismatch repair proteins in sebaceous gland tumors.
Popnikolov NK; Gatalica Z; Colome-Grimmer MI; Sánchez RL
J Cutan Pathol; 2003 Mar; 30(3):178-84. PubMed ID: 12641777
[TBL] [Abstract][Full Text] [Related]
14. Sebaceous gland tumors of the eyelids and conjunctiva in the Muir-Torre syndrome: a clinicopathologic study of five cases and literature review.
Rishi K; Font RL
Ophthalmic Plast Reconstr Surg; 2004 Jan; 20(1):31-6. PubMed ID: 14752307
[TBL] [Abstract][Full Text] [Related]
15. [Muir-Torre syndrome and Turcot syndrome].
Velter C; Caussade P; Fricker JP; Cribier B
Ann Dermatol Venereol; 2017; 144(8-9):525-529. PubMed ID: 28256262
[TBL] [Abstract][Full Text] [Related]
16. Muir-Torre syndrome.
Cohen PR; Kohn SR; Davis DA; Kurzrock R
Dermatol Clin; 1995 Jan; 13(1):79-89. PubMed ID: 7712655
[TBL] [Abstract][Full Text] [Related]
17. "Second hit" in sebaceous tumors from Muir-Torre patients with germline mutations in MSH2: allele loss is not the preferred mode of inactivation.
Kruse R; Rütten A; Hosseiny-Malayeri HR; Bisceglia M; Friedl W; Propping P; Ruzicka T; Mangold E
J Invest Dermatol; 2001 Mar; 116(3):463-5. PubMed ID: 11231323
[TBL] [Abstract][Full Text] [Related]
18. Eyelid sebaceous carcinoma associated with Muir-Torre syndrome in two cases.
Demirci H; Nelson CC; Shields CL; Eagle RC; Shields JA
Ophthalmic Plast Reconstr Surg; 2007; 23(1):77-9. PubMed ID: 17237705
[TBL] [Abstract][Full Text] [Related]
19. Cystic sebaceous tumors as marker lesions for the Muir-Torre syndrome: a histopathologic and molecular genetic study.
Rütten A; Burgdorf W; Hügel H; Kutzner H; Hosseiny-Malayeri HR; Friedl W; Propping P; Kruse R
Am J Dermatopathol; 1999 Oct; 21(5):405-13. PubMed ID: 10535567
[TBL] [Abstract][Full Text] [Related]
20. [Female patient with Muir-Torre syndrome].
Negraszus N; Jöhrens K; Bertelmann E
Ophthalmologe; 2010 Nov; 107(11):1059-62. PubMed ID: 20393721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
